I.G. Investment Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$1.09M Hold
30,000
0.01% 319
2017
Q2
$1.18M Hold
30,000
0.01% 313
2017
Q1
$941K Hold
30,000
﹤0.01% 343
2016
Q4
$937K Sell
30,000
-476,181
-94% -$15.4M ﹤0.01% 337
2016
Q3
$20.3M Sell
506,181
-5,004
-1% -$188K 0.08% 159
2016
Q2
$17M Buy
511,185
+179,460
+54% +$6.14M 0.07% 174
2016
Q1
$9.75M Sell
331,725
-141,774
-30% -$3.91M 0.04% 247
2015
Q4
$12.5M Buy
473,499
+360,759
+320% +$9.37M 0.05% 197
2015
Q3
$2.67M Buy
112,740
+73,014
+184% +$1.76M 0.01% 421
2015
Q2
$943K Buy
39,726
+9,582
+32% +$216K ﹤0.01% 659
2015
Q1
$716K Buy
+30,144
New +$676K ﹤0.01% 703
2014
Q4
Sell
-52,200
Closed -$889K 868
2014
Q3
$889K Buy
52,200
+4,200
+9% +$66.3K ﹤0.01% 611
2014
Q2
$687K Sell
48,000
-249,030
-84% -$3.38M ﹤0.01% 699
2014
Q1
$3.67M Buy
297,030
+1,080
+0.4% +$12.5K 0.01% 374
2013
Q4
$3.24M Buy
+295,950
New +$3.34M 0.01% 385

Other funds holding EW

I.G. Investment Management's EW Position: Q3 2017 in Review

I.G. Investment Management held its Edwards Lifesciences (EW) position steady in Q3 2017 at 30,000 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #319.

I.G. Investment Management first reported a position in EW in Q4 2013 and has held it in 15 quarters since. The position peaked at $20.3M in Q3 2016. 739 funds tracked by Wall St. Rank hold EW as of Q3 2017.

  • I.G. Investment Management held 30,000 shares of Edwards Lifesciences worth $1.09M as of Q3 2017.
  • I.G. Investment Management left its Edwards Lifesciences share count unchanged in Q3 2017.
  • Edwards Lifesciences made up 0.01% of I.G. Investment Management's portfolio in Q3 2017, its #319 holding.
  • I.G. Investment Management first reported a position in Edwards Lifesciences in Q4 2013 and has held it in 15 quarters since.
  • I.G. Investment Management's Edwards Lifesciences position peaked at $20.3M in Q3 2016.
  • 739 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2017.

Based on I.G. Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.